We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Vela Laboratories and Anagnostics Enter Strategic Partnership

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vela Laboratories and Anagnostics Enter Strategic Partnership"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Viennese Vela Laboratories are among the leading companies offering efficacy and release testing for biopharmaceuticals under GMP conditions (Good Manufacturing Practice).

Vela Laboratories and Anagnostics have agreed upon a strategic partnership in the fields of analytical services and marketing and sales in the area of services for drug discovery units.

‘The fast growing demand in the field of Biosimilars - Comparability Testing results in a need for creative business models. Vela obtained international reputation within the market for complete characterization of Biopharmaceuticals, Biologics and Biosimilars and is among the top tier suppliers of ICH Q6B conform protein analytics.

Anagnostics hybcell technology offers totally new analytical solutions, which we want to offer our customers.

Together we can serve our customers more efficiently and comprehensively’ comments Dr. Markus Fido, CEO of Vela Laboratories, the decision of his company.

‘Synergies stemming from Anagnostics’ innovative analytical approaches and the outstanding expertise of Vela Laboratories enable Anagnostics to speed up the market penetration in the field of drug discovery’, is highlighted by Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH.

Patient stratification / Affinity Measurement
In a first step Anagnostics’ compact sequencing should be applied for patient stratification during clinical studies - for example a test for mutations in the KRAS and BRAF gene.

In a second step Anagnostics’ affinity and immunogenicity measurement will be applied for the characterization of drug candidates.

In comparison to methods like SPR (surface plasmon resonance) hybcell offers far more capacity for simultaneous examinations of samples and is less vulnerable to interferences (higher selectivity). Another aspect is the ability of hybcell tests to be stored over long periods of time.

Especially for long-term projects this aspect could be an advantage for researchers, as they can compare new drug candidates under the same conditions that were applied for examinations earlier in the project.